Intellia Therapeutics issues equity awards to new hires under inducement plan
Intellia Therapeutics has granted restricted stock units to eight new employees as a direct incentive to join, using its 2024 Inducement Plan.
Intellia Therapeutics 1 article
The biotechnology profile of Intellia Therapeutics is built around in vivo CRISPR editing and CRISPR Cas9 genetic medicines, placing it in targeted genetic medicine rather than conventional gene addition. The platform further combines lipid nanoparticle CRISPR delivery with liver-directed genome editing, with systemic in vivo gene knockout defining an important delivery, nuclease, cell-processing or disease-specific aspect of the editing strategy. For entity matching, genome editing is the modality rather than the organization; Intellia Therapeutics is also associated with transthyretin gene editing.